Ertapenem Susceptibility of Extended Spectrum Beta-Lactamase Producing E Coli and K Pneumoniae
Keywords:
Escherichia coli, Ertapenem, ESBL, Imipenem and K. pneumoniasAbstract
Background: Multidrug resistant organism such as extended spectrum beta-lactamase (ESBL) – producing E. coli and K. pneumoniae are increasing in critical ill patients. Carbapenem [Imipenem and Meropenem] are the antibiotics of choice to treat them. Ertapenem, newest Carbapenem has limited clinical data regarding its efficacy against these organisms.
Objectives: Objective of study is to compare susceptibility of ertapenem to imipenem and organisms are susceptibility of ertapenem to imipenem could be used as a surrogate for ertapenem susceptibility.
Materials and Methods: 53 ESBL isolates (n==26 E –coli and n==27 K. pneumoniae) collected from critical care unit specimen were identified tested susceptibility by Vitek 2 compact (Biomerieux India pvt. LTD.)
Result: 100% of clinical isolates tested were susceptible to ertapenem. 100% of same isolates were also susceptible to imipenem.
Conclusion: 100% susceptibility, suggest that ertapenem may be an alternative to other carbapenem for the treatment of infection caused by ESBL_ producing E-coli and K.pneumoniae.
References
Livermore D, Okakton K, Carter M, Warner M : Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with Potent Beta-Lactamases. Antimicrob Agents Chemother 2001.
Rupp M, Fey P: Extended Spectrum beta-lactamase (ESBL) -Producing Enterobacteriaceae: Considerations for Diagnosis, Prevention, and drug treatment. Drugs 2003.
Jacoby G, Mills D, Chow N: Role of beta-Lactamases and porins in resistance to Ertapenem and other beta-Lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004.
Colodner R, Raz R: Extended -Spectrum Beta -Lactamase: The end of Cephalosporins? IMAJ2005.
Jacoby G, Munoz-Price L: Mechanisms of Disease: The New (beta)-Lactamases. N Eng J Med2005.
Paterson D, Rossi F, Hsueh P, Woods GL, Satishchan-dran V, Snyder TA, Harvey CM, Teppler H, DiNubile MJ, Chow JW: In vitro susceptibilites of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends(SMART). J Antimicrob Chemother 2005.
Aronson N, Sanders J, Moran K: In Harm's Way: Infec-tion in Deployed American Military Forces. Clin Inf Dis 20066)
AB BIODISK E Test Ertapenem Package insert. AB BIODISK, SolnaSweden 2006.
Betriu C, Salso S, SanCez A, Culebras E, Gomez M, Ro-driguez-Avial I,Picazo J: Comparative in vitro activity and the inoculum effect of ertapenem agaist Enterobac-teriaceae resistent to extended-spectrum cephalosporins. Int J Antimicrob Agents 2006.
Clinical and Laboratory Standerd Institute (CLSI): Per-formance Standerd for Antimicrobial susceptibility Test-ing. 16th informational supplement. CLSI document M100-S16. Wayne, PA 2006.
Elliott E, Brink A, van Greune J, Els Z, Woodford N, Turton J, Warner M, Livermoe DM: In vivo devlopment of Ertapenem resistance in a patient with pneumonea caused by Klebsiella pneumoniae with an Extended -Spectrum beta-Lactamase. Clin Inf Dis2006.
Ramphal R, Ambrose P: Extended-Spectrum beta-lactamases and Clinical outcomes: Current Data. Clin Inf Dis 2006.
Lartigue M, Poirel L, Poyart C, Reglier-Poupet H, Nordmann P:Ertapenem Resistance of Escherichia coli. Emerging inf Dis 2007.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
